New treatment for lung fibrosis related to scleroderma
TT-036 for the treatment of scleroderma-associated pulmonary fibrosis
['FUNDING_OTHER'] · THENDOR THERAPEUTICS LLC · NIH-11006098
This study is looking at a new treatment made from collagen that could help people with lung fibrosis caused by scleroderma, aiming to improve their health and quality of life more effectively than current options.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | THENDOR THERAPEUTICS LLC (nih funded) |
| Locations | 1 site (LEXINGTON, UNITED STATES) |
| Trial ID | NIH-11006098 on ClinicalTrials.gov |
What this research studies
This research investigates a novel peptide derived from collagen XVIII that may help treat lung fibrosis associated with scleroderma. The approach focuses on its anti-fibrotic effects observed in both animal models and human pre-clinical studies. By targeting the underlying mechanisms of fibrosis, the research aims to provide a more effective treatment option compared to existing therapies that only slow disease progression. Patients with severe lung fibrosis may benefit from this innovative treatment, which could improve their quality of life and health outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with scleroderma who are experiencing lung fibrosis.
Not a fit: Patients with lung fibrosis not related to scleroderma or those who have already undergone lung transplantation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new therapy that effectively reduces lung fibrosis and improves survival rates for patients with scleroderma.
How similar studies have performed: While there have been studies on various treatments for lung fibrosis, this specific approach using collagen-derived peptides is novel and has not been extensively tested in clinical settings.
Where this research is happening
LEXINGTON, UNITED STATES
- THENDOR THERAPEUTICS LLC — LEXINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FEGHALI-BOSTWICK, CAROL A. — THENDOR THERAPEUTICS LLC
- Study coordinator: FEGHALI-BOSTWICK, CAROL A.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers